Adolescence

Limbix Partners with the Children's Hospital Los Angeles to Study SparkRx

Retrieved on: 
Tuesday, September 6, 2022
Cardiology, Partnership, COVID-19, Research, Diathesis–stress model, Division, Children's Hospital Los Angeles, Smartphone, Gastroenterology, Ageing, CBT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAN, Comfort, Doctor of Philosophy, PTSD, Behavior, Suicide, Cognitive behavioral therapy, Palliative care, Food, Department, Grammatical mood, Principal, Adolescence, Reading, Depression, CHLA, Behavioral activation, Anesthesiology, Patient, Lists of diseases, Degenerative disease, FDA, Therapy, Population, Arousal, Mental health, Language isolate, Self-harm, Risk, Suicidal ideation, Pharmaceutical industry, Hospital, Residential care

SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Limbix is excited to announce a partnership with Children's Hospital Los Angeles (CHLA) for a research study to evaluate SparkRx , an adjunct treatment for adolescents with symptoms of depression, in specialty medical care settings.

Key Points: 
  • SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Limbix is excited to announce a partnership with Children's Hospital Los Angeles (CHLA) for a research study to evaluate SparkRx , an adjunct treatment for adolescents with symptoms of depression, in specialty medical care settings.
  • SparkRx is a self-guided, cognitive behavioral therapy (CBT)-based digital therapeutic intervention for adolescents, aged 13-22 years old.
  • "We are especially excited to partner with Children's Hospital Los Angeles to run this research study in specialty care settings to better understand the mental health needs of this patient population."
  • Through extensive research, Limbix built their first digital therapeutic, SparkRx, that delivers CBT-based treatment directly to each user's smartphone.

Spexis provides business update and announces financial results for the first half of 2022

Retrieved on: 
Tuesday, September 6, 2022
CF, Mortality, Partnership, Docetaxel, CEO, Gram-negative bacteria, Safety, Program, Development, Chief executive officer, IRIS, Kidney, Rigidity, R, Total, LR, Chronic obstructive pulmonary disease, Ethics, Adolescence, Cystic fibrosis, GLOBE, Gordon, CHF, Conference, Company, FDA, COPD, Urinary tract infection, Therapy, CFTR, Adult, Clinical trial, Conference call, COPA, CXCR4, Patient, Pharmaceutical industry, Fine chemical, Spexy Beast

ALLSCHWIL, Switzerland, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced its financial results for the first half of 2022 and provided a strategic business update.

Key Points: 
  • Despite the ongoing very challenging financial markets, we continue to make steady progress with Spexis, said Jeff Wager, M.D., Chairman & CEO of Spexis.
  • The plans outlined below regarding the further development of various programs are subject to Spexis raising additional funds and/or entering into partnering agreements.
  • Spexis is looking to partner either these pre-clinical leads or the entire platform itself, potentially in combination with complementary technologies.
  • On July 28, 2022, Spexis announced that it had renewed an equity-linked financing arrangement with the French company IRIS.

Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older

Retrieved on: 
Thursday, September 1, 2022
NVAX, Nanoparticle, Partnership, Security (finance), COVID-19, U.S. Securities and Exchange Commission, Safety, Vaccination, Ageing, Government, Coronavirus, World, Global health, Antigen presentation, Risk, Infection, Result, Volunteering, Conversation, SEC, Serum Institute of India, Genetic engineering, Adolescence, Review, Lymph, Severe acute respiratory syndrome coronavirus 2, The New England Journal of Medicine, Biotechnology, Financial condition report, EC, Adult, Clinical trial, Annual report, Analysis, COVID, B cell, Health, Omicron, Novavax COVID-19 vaccine, World Health Organization, Vaccine, Pharmaceutical industry, NEJM, Novavax, Delta

The vaccine is stored at 2- 8 Celsius, enabling the use of existing vaccine supply and cold chain channels.

Key Points: 
  • The vaccine is stored at 2- 8 Celsius, enabling the use of existing vaccine supply and cold chain channels.
  • Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India, the world's largest vaccine manufacturer by volume.
  • The Novavax COVID-19 vaccine, has received authorization from multiple regulatory authorities globally, including the U.S., EC and the World Health Organization.
  • These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older

Retrieved on: 
Thursday, September 1, 2022
NVAX, Nanoparticle, Partnership, Security (finance), COVID-19, U.S. Securities and Exchange Commission, Safety, Vaccination, Ageing, Government, Coronavirus, World, Global health, Antigen presentation, Risk, Infection, Result, Volunteering, Conversation, SEC, Serum Institute of India, Genetic engineering, Adolescence, Review, Lymph, Severe acute respiratory syndrome coronavirus 2, The New England Journal of Medicine, Biotechnology, Financial condition report, EC, Adult, Clinical trial, Annual report, Analysis, COVID, B cell, Health, Omicron, Novavax COVID-19 vaccine, World Health Organization, Vaccine, Pharmaceutical industry, NEJM, Novavax, Delta

The vaccine is stored at 2- 8 Celsius, enabling the use of existing vaccine supply and cold chain channels.

Key Points: 
  • The vaccine is stored at 2- 8 Celsius, enabling the use of existing vaccine supply and cold chain channels.
  • Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India, the world's largest vaccine manufacturer by volume.
  • The Novavax COVID-19 vaccine, has received authorization from multiple regulatory authorities globally, including the U.S., EC and the World Health Organization.
  • These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Former NFL Quarterback Ray Lucas Shares Personal Story of Opioid Addiction and Recovery with Harrison High School Student Athletes

Retrieved on: 
Tuesday, August 30, 2022
Harrison, Advertising, Pain, Program, Horizon Blue Cross Blue Shield of New Jersey, New Jersey State Interscholastic Athletic Association, Connecting, Addiction, Swimming, Government, Harrison High School, Gymnastics, Baseball, Rutgers University, Partnership, Golf, Illegal drug trade, National Federation of State High School Associations, Blue, NJSIAA, Crown, Blue Shield, Sport, Association, Tennis, Blue Cross Blue Shield Association, Wrestling, Football, Volleyball, Blue Cross, Adolescence, Education, Student, Plague, Organization, Athlete, Harrison High School (New Jersey), Hospital, Center, Drug, Communication, Korea Disease Control and Prevention Agency, Risk, Injury, NFL, Naloxone, Basketball, Future, Patient, Medicine, Pharmaceutical industry, Health insurance

On Tuesday, student athletes at Harrison High School received an education on the risks of prescription opioids from a familiar face, Harrison native and former NFL quarterback Ray Lucas.

Key Points: 
  • On Tuesday, student athletes at Harrison High School received an education on the risks of prescription opioids from a familiar face, Harrison native and former NFL quarterback Ray Lucas.
  • It was the second of 10 events to be held for high school students through the 2022-23 school year and the first to be held in-person.
  • Sports injuries happen in high school sports so makesure to ask the questions about what you are being prescribed for pain and if there are alternatives, Lucas said.
  • A member of the National Federation of State High School Associations, the NJSIAA conducts tournaments and crowns champions in 33 sports.

Health-E Commerce announces partnership with Byte® to offer doctor-directed at-home invisible aligner solutions to straighten and whiten teeth on FSAstore and HSAstore

Retrieved on: 
Monday, August 29, 2022
Commerce, Partnership, Dentsply Sirona, FSA, XRAY, HSAS, HSA, Orthodontics, Mark (given name), Adolescence, Children's Health Fund, Nib Health Funds, Currency strap, Brace, Adult, Dentist, Adoption, Health insurance, Dentistry, Byte

NEW YORK, Aug. 29, 2022 /PRNewswire-PRWeb/ -- At an average of $3,000 to $7,500, getting braces may not be attainable for many individuals – whether you're an adult or adolescent. Fortunately, orthodontics are eligible for reimbursement with a flexible spending account (FSA) or health savings account (HSA), and a new partnership between Health-E Commerce and Byte is making it easier and more affordable to use tax-free healthcare dollars for Doctor Directed Invisible braces. Health-E Commerce is the parent brand to FSAstore.com and HSAstore.com, the first and largest online marketplaces dedicated to selling only items that are eligible for reimbursement with FSA or HSA funds.

Key Points: 
  • The partnership makes the Byte impression kit available for just $12.95 on FSAstore.com and HSAstore.com , and offers FSA and HSA account holders a $200 discount on Byte invisible aligners.
  • "The number of adults getting braces continues to increase , and not just for cosmetic reasons.
  • Improperly spaced teeth can affect your bite and cause serious dental and health issues," said Zack Peckham, vice president of strategy, Health-E Commerce.
  • Since 2010, the Health-E Commerce brands have led the direct-to-consumer e-commerce market for exclusively pre-tax health and wellness benefits.

United States Digital Therapeutics Market Trends/Analysis Report 2022-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 26, 2022
Technology, Health Technology, Health, Wearables, Mobile Technology, Partnership, UDI, CVS, COVID-19, Public health, Conditional sentence, Opioid use disorder, Diabetes, Digital, Therapy, Employment, Single-frequency network, Unique Device Identification, Solution, Disease, Self-management, Incidence, USD, Adolescence, Depression, Psychosis, Patient, Lists of diseases, FDA, Providers, CAGR, Growth, Adoption, Medical device, Pharmaceutical industry, Health insurance, Pear, Obesity

The "U.S. Digital Therapeutics Market Size, Share & Trends Analysis Report by Application (Diabetes, Obesity, CNS Diseases, Others), by End Use (Patients, Providers, Payers, Employers, Others), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Digital Therapeutics Market Size, Share & Trends Analysis Report by Application (Diabetes, Obesity, CNS Diseases, Others), by End Use (Patients, Providers, Payers, Employers, Others), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Growing healthcare consumerism, the availability & development of DTx products, and the rising number of market players are driving the regional market.
  • SparkRx by Limbix Health, for example, is a digital therapeutic that is indicated for the treatment of adolescent depression.
  • The digital therapeutics market in the U.S. was valued at USD 1.5 billion in 2021 and is expected to advance at a CAGR of 24.8% during the forecast period.

Kozyavkin Program restores hope for patients at Cambridge Medical & Rehabilitation Center

Retrieved on: 
Friday, August 26, 2022
Trigger, Adolescence, CARF, Muscle, Drug, Program, JCI, CP, United Arab Emirates, Occupational therapy, Accident, Traffic, Kingdom, Speech–language pathology, CMRC, Rehabilitation, Press release, Physician, AND, Infant, Quality of life, Freedom, Infection, GCC, Brain damage, Patient, Movement, Massage, HOPE, Iffat bint Mohammad Al Thunayan, Stroke, Long-term care, Hypoxia, Motion, Her Humble Ministry, KSA, Cerebral palsy, Improving Medicare Post-Acute Care Transformation Act of 2014, Child, Residential care, Hospital, Healthcare

ABU DHABI, UAE, Aug. 26, 2022 /PRNewswire/ -- Cambridge Medical & Rehabilitation Center (CMRC), the leading GCC Rehabilitation and Long-Term Care provider ensuring a "continuum of care" to its patients, today announced the newest success story for their Kozyavkin Program. The highly effective rehabilitation treatment is aimed at patients with Cerebral Palsy (CP) or other neurological conditions that affect freedom of movement. Young Thunayan is the latest of CMRC's walking success stories.

Key Points: 
  • THE LEADER IN REHABILITATION IN THE GCC REGION OFFERS CEREBRAL PALSY PATIENTS, AND THEIR FAMILIES HOPE WITH THE KOZYAVKIN METHOD
    ABU DHABI, UAE, Aug. 26, 2022 /PRNewswire/ -- Cambridge Medical & Rehabilitation Center (CMRC) , the leading GCC Rehabilitation and Long-Term Care provider ensuring a "continuum of care" to its patients, today announced the newest success story for their Kozyavkin Program.
  • Dr. Howard Podolsky, Group Chief Executive Officer, commented, "Cambridge Medical and Rehabilitation Center is humbled and privileged to provide innovative and ground-breaking care to patients such as Thunayan.
  • Cambridge Medical and Rehabilitation Center has a high weaning rate for mechanically ventilated patients demonstrating that CMRC achieves the mission of enhancing the quality of life for its patients and their families.
  • Cambridge Medical and Rehabilitation Center uses the most current, internationally accepted evidence-based clinical practices that help patients overcome their obstacles and fulfill their needs in restoring their capacity and aiming for a better quality of life.

Kozyavkin Program restores hope for patients at Cambridge Medical & Rehabilitation Center

Retrieved on: 
Friday, August 26, 2022
Trigger, Adolescence, CARF, Muscle, Drug, Program, JCI, CP, United Arab Emirates, Occupational therapy, Accident, Traffic, Kingdom, Speech–language pathology, CMRC, Rehabilitation, Press release, Physician, AND, Infant, Quality of life, Freedom, Infection, GCC, Brain damage, Patient, Movement, Massage, HOPE, Iffat bint Mohammad Al Thunayan, Stroke, Long-term care, Hypoxia, Motion, Her Humble Ministry, KSA, Cerebral palsy, Improving Medicare Post-Acute Care Transformation Act of 2014, Child, Residential care, Hospital, Healthcare

ABU DHABI, UAE, Aug. 26, 2022 /PRNewswire/ -- Cambridge Medical & Rehabilitation Center (CMRC), the leading GCC Rehabilitation and Long-Term Care provider ensuring a "continuum of care" to its patients, today announced the newest success story for their Kozyavkin Program. The highly effective rehabilitation treatment is aimed at patients with Cerebral Palsy (CP) or other neurological conditions that affect freedom of movement. Young Thunayan is the latest of CMRC's walking success stories.

Key Points: 
  • THE LEADER IN REHABILITATION IN THE GCC REGION OFFERS CEREBRAL PALSY PATIENTS, AND THEIR FAMILIES HOPE WITH THE KOZYAVKIN METHOD
    ABU DHABI, UAE, Aug. 26, 2022 /PRNewswire/ -- Cambridge Medical & Rehabilitation Center (CMRC) , the leading GCC Rehabilitation and Long-Term Care provider ensuring a "continuum of care" to its patients, today announced the newest success story for their Kozyavkin Program.
  • Dr. Howard Podolsky, Group Chief Executive Officer, commented, "Cambridge Medical and Rehabilitation Center is humbled and privileged to provide innovative and ground-breaking care to patients such as Thunayan.
  • Cambridge Medical and Rehabilitation Center has a high weaning rate for mechanically ventilated patients demonstrating that CMRC achieves the mission of enhancing the quality of life for its patients and their families.
  • Cambridge Medical and Rehabilitation Center uses the most current, internationally accepted evidence-based clinical practices that help patients overcome their obstacles and fulfill their needs in restoring their capacity and aiming for a better quality of life.

With Back to School Comes Back to Sleep: Third Annual Student Sleep Health Week to be Held Sept. 12-18

Retrieved on: 
Thursday, August 25, 2022
National Association, Patient, Research, AASM, Sleep, Physiology, American Academy, House, Physical education, American Academy of Sleep Medicine, Journal of Clinical Sleep Medicine, Behavior, Memory, Parent, Sport, EDT, Habit, Physician, Learning, Adolescence, Reading, Education, Student, Journal, GLOBE, Attention, Mental health, National Association of School Nurses, Representative, AMA, Health, Society, Life, Regulation, Social media, Medicine, Pharmaceutical industry, Tutoring

The American Academy of Sleep Medicine is holding the third annual Student Sleep Health Week Sept. 12-18, 2022, to educate students, parents and educators about the importance of sleep for success, well-being and overall health.

Key Points: 
  • The American Academy of Sleep Medicine is holding the third annual Student Sleep Health Week Sept. 12-18, 2022, to educate students, parents and educators about the importance of sleep for success, well-being and overall health.
  • Research shows that students who get healthy sleep experience better outcomes, including improved attention, behavior, learning, memory, emotional regulation, and mental and physical health.
  • A recent study published in the Journal of Clinical Sleep Medicine shows that poor sleep habits in adolescence contributed to poor health outcomes in adulthood.
  • Student Sleep Health Week is presented in conjunction with supporting partners American School Counselor Association , National Association of School Nurses, Project Sleep , Sleep Research Society , Society of Health and Physical Educators and Start School Later .